December 22, 2017 — Median Technologies recently announced a research collaboration agreement with Xingtai People's Hospital, Xingtai City, China. Within the frame of the agreement, Median's MediScan image analysis technology will be used to conduct lung cancer screening programs organized under the aegis of Xingtai People's Hospital in Xingtai City. These programs are critically important to improving the health of the people of Xingtai City since the incidence of and mortality associated with lung cancer have increased dramatically in China and become a nationwide public health issue, giving rise to an increased burden on patients, healthcare professionals and society.
Healthcare professionals at Xingtai People's Hospital will use MediScan for the identification and monitoring of suspicious nodules found in pulmonary computed tomography (CT) scans of asymptomatic patients. Thanks to the use of MediScan in screening programs by Xingtai People's Hospital, the population of Xingtai will have access to cutting-edge software technology based on artificial intelligence principles, specifically designed to transform the identification and management of cancer lesions found in medical images.
Median's Mediscan technology provides advanced functionalities for the automated detection, quantification and follow-up of various abnormalities, including suspicious pulmonary nodules, visible in CT images. The technology will enable Xingtai People's Hospital health professionals to optimize the detection of pulmonary nodules in screened populations, enabling earliest detection of suspicious lesions in patients. Many medical reports and scientific publications show that early detection of lung cancer greatly increases the chances for successful treatment.
For more information: www.mediantechnologies.com
October 13, 2026 
